April 11, 2003
"A viral load at treatment week four above 450,000 IU/mL and at week 12 above 30,000 IU/mL was 100 percent predictive for virologic nonresponse in all patients," reported Thomas Berg and colleagues of Humboldt University-Berlin. Statistical analysis indicated that being of HCV of genotypes 2 or 3, having high levels of alanine aminotransferase before starting treatment, and having a low viral load at baseline were independent predictors for attaining a sustained virologic response.
"None of the latter three factors were predictive for sustained virologic response when analysis was restricted to the subgroup of genotypes 2- and 3-infected patients," Berg and coauthors wrote. They suggested that by as early as 12 weeks after therapy has begun, doctors can determine whether or not sustained virological response will occur using a HCV RNA cut-off level 30,000 IU/mL. "This algorithm recognizes 53.7 percent of nonresponders previously identified at week 24 of treatment," they said.
The full study, "Prediction of Treatment Outcome in Patients with Chronic Hepatitis C: Significance of Baseline Parameters and Viral Dynamics During Therapy," was published in Hepatology (2003;37(3):600-609).
03.31.03; Sonia Nichols
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Separate and Unequal Access Frames Discussion at CROI Panel on U.S. HIV Care Cascade|
|CROI 2018: Highlights and What's Next for Advocates|
|Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence|
|Injection Drug Use Among People Living With HIV: A Missed Opportunity to Save Lives|
|Statin Use Might Reduce Risk of Cancer in HIV-Positive People|
|Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say|